Human immunodeficiency virus 1 envelope glycoprotein gp120 N332 glycan supersite (gp120 N332 supersite)

The HIV-1 envelope glycoprotein gp120 N332 glycan supersite is a critical region of vulnerability on the HIV-1 envelope trimer, primarily defined by the N-linked glycan at position 332. This site is a major target for potent broadly neutralizing antibodies (bNAbs) such as PGT121 and 10-1074, which recognize a cluster of high-mannose glycans and the underlying protein scaffold, including the V3 loop base and parts of the V1 loop. Biologically, this region is essential for the structural integrity of the envelope spike and its function in mediating viral entry into host CD4+ T cells. In the context of disease, the N332 supersite is a focal point for vaccine development and passive immunotherapy aimed at preventing or controlling HIV-1 infection. Therapeutic agents targeting this site work by binding to the supersite and preventing the conformational changes required for viral fusion. However, the high mutation rate of HIV-1 can lead to the loss of the N332 glycan or structural shifts in the surrounding loops, resulting in viral escape and resistance to these therapies. The site is characterized by a dense cluster of oligomannose-type glycans that are relatively rigid, providing a stable target for antibody recognition despite the overall variability of the virus. Clinical studies of antibodies targeting this region have shown promise in suppressing viral load in HIV-infected individuals and protecting against infection in animal models.

Other names

N332-supersiteV3-glycan supersitePGT121-binding site10-1074-binding siteMan9-rich glycan clusterV3-glycan regiongp120 V1/V3 glycan patch

Neutralization of HIV-1 by binding to the N332 glycan and surrounding protein motifs, thereby blocking viral attachment to CD4 receptors and preventing the conformational changes necessary for membrane fusion.